NCT00079612已完成2 期
Randomized Discontinuation Study of BAY 43-9006 in Patients With Advanced Refractory Cancer.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 501
- 主要终点
- Number of progressions post randomization to placebo or sorafenib
研究概览
简要总结
The purpose of the study is to:
- Find out if BAY 43-9006 prevents the growth of tumors
- For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time.
- Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY 43-9006 (sorafenib) in the treatment of advanced refractory cancers.
- Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years- Patients with refractory solid cancer for which curative or palliative measures have failed or patients whose treatments are considered ineffective or intolerable
- •Patients with non-colorectal cancers are eligible and must be progressing at the time of the screening assessment and for whom no other treatment exists
- •Patients with at least one (1) measurable tumor, per the WHO Tumor Response Criteria - Histological or cytological documentation of cancer- ECOG Performance status 0 or 1
- •Life expectancy of at least 12 weeks- Adequate bone marrow, liver and renal function (assessed by the following laboratory requirements):
- •Hemoglobin >/= 9.0 g/dl - Absolute neutrophil count (ANC) >/=1,500/mm3
- •Platelet count = 100,000/µl3
- •Total bilirubin </=1.0 times the upper limit of normal unless due to Gilbert's
- •ALT and AST </= 2.5 x upper limit of normal. (For patients with hepatic involvement of their cancer, ALT and AST < 5.0 x upper limit of normal)
- •PT-INR/PTT < 1.5 x upper limit of normal. (Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.
- •In addition, these patients must be monitored with weekly coagulation assessments throughout the Run-in Period)- Serum creatinine < 1.5 x upper limit of normal
排除标准
- •Patients who meet the following criteria at the time of screening will be excluded:
- •Non small cell lung cancer, hepatocellular cancer, CML and AML
- •Serious cardiac arrhythmia
- •Congestive Heart Failure (NYHA Class 3 or 4)
- •Active of coronary artery disease or ischemia
- •Active acute infections that could be worsened by anticancer therapy or interfere with this study
- •Known HIV infection
- •Metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry
- •Patients currently receiving medication (steroid or anticonvulsant therapy) for seizure disorder
- •History of organ allograft- Previous or concurrent cancer that is distinct from the cancer being evaluated in this study. Several situations are excluded, including cervical carcinoma in situ, adequately treated basal cell carcinoma, superficial bladder tumors or any cancer definitively treated greater than 3 years
- •Anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to the first dose of study drug
- •Radiotherapy during the study or within 3 weeks prior to the first dose of study drug
- •Bone marrow transplant or stem cell rescue within 4 months prior to the first dose of study drug
- •Biological response modifiers, such as G-CSF within 3 weeks prior to study entry
- •Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study
- •Investigational drug therapy outside of this trial during or within 4 weeks prior to the screening assessment
- •Any previous exposure to a Ras pathway inhibitor
- •Pregnant or breast feeding patients. Women of child bearing potential must have a negative pregnancy test. Adequate barrier contraception will be required for both male and female patients during the entire course of the trial
- •Substance abuse, medical or psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- •Known or suspected allergy to the investigational agent or any agent given in association with the trial
- •Any condition that is unstable or could jeopardize the safety of the patient and/or their compliance in the study
研究组 & 干预措施
Arm 1
Experimental
干预措施: Sorafenib (Nexavar, BAY43-9006) (Drug)
Arm 2
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of progressions post randomization to placebo or sorafenib
时间窗: 12 weeks post randomization
次要结局
- Time to progression(Until Progression occurs)
- Overall survival time(At the End-of-Study visit)
- Duration of objective tumor response(Time from initial Response to documented Tumor Progression)
研究者
相似试验
已完成
2 期
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)Carcinoma, Non-Small Cell LungCancerNCT00101413Bayer52
已完成
2 期
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic MelanomaMelanomaNCT00492297Bayer83
已完成
2 期
BAY43-9006 - Phase II in Advanced Breast CancerBreast NeoplasmsBreast CancerNCT00101400Bayer54
已完成
2 期
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell CarcinomaCarcinoma, Renal CellNCT00117637Bayer189
已完成
2 期
Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck CancerHead and Neck NeoplasmsNCT00199160Jules Bordet Institute60